Coya Therapeutics, Inc.
COYA
$4.54
$0.255.83%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 123.57% | -58.26% | -95.57% | -39.87% | -40.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 123.57% | -58.26% | -95.57% | -39.87% | -40.79% |
| Cost of Revenue | 41.03% | 19.01% | 19.55% | 88.20% | 115.68% |
| Gross Profit | -5.74% | -391.24% | -833.21% | -701.98% | -1,760.00% |
| SG&A Expenses | 28.85% | 13.07% | 12.50% | 6.36% | 13.43% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.77% | 16.36% | 16.37% | 44.13% | 55.50% |
| Operating Income | -17.65% | -80.39% | -120.70% | -96.04% | -134.02% |
| Income Before Tax | -36.04% | -92.01% | -124.61% | -86.40% | -114.77% |
| Income Tax Expenses | 100.43% | -199.50% | -199.50% | -199.50% | -199.50% |
| Earnings from Continuing Operations | -42.64% | -72.29% | -101.38% | -66.31% | -86.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.64% | -72.29% | -101.38% | -66.31% | -86.29% |
| EBIT | -17.65% | -80.39% | -120.70% | -96.04% | -134.02% |
| EBITDA | -17.68% | -80.59% | -121.03% | -96.31% | -134.53% |
| EPS Basic | -28.71% | -59.66% | -61.00% | -20.62% | -19.93% |
| Normalized Basic EPS | -10.12% | -84.11% | -87.23% | -45.12% | -46.09% |
| EPS Diluted | -28.71% | -59.66% | -61.00% | -20.62% | -19.93% |
| Normalized Diluted EPS | -10.12% | -84.11% | -87.23% | -45.12% | -46.09% |
| Average Basic Shares Outstanding | 9.79% | 19.61% | 29.13% | 39.27% | 49.93% |
| Average Diluted Shares Outstanding | 9.79% | 19.61% | 29.13% | 39.27% | 49.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |